Inhibition of SEMA3C‐induced and cognate ligand‐induced RTK pathway activation with B1SP decoy receptor therapeutic protein represents a new therapeutic strategy that can be used as a single agent or in biologically rational combinations with AR pathway inhibitors and/or TKIs for treatment of advanced prostate cancer. This evidence concerns the gene AR and prostate carcinoma.